Optineurin is a 66 kDa ubiquitin-binding protein encoded by the OPTN gene [@minegishi2013]. It is a versatile adaptor protein involved in multiple cellular processes including autophagy, inflammation, and membrane trafficking [@gandhi2014]. OPTN has emerged as a critical player in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and glaucoma [@maruyama2010].
OPTN was originally identified as a binding partner of adenovirus E3-14.7K protein and later shown to interact with myosin VI, suggesting roles in membrane trafficking and cellular signaling [@wain2011]. The protein contains multiple functional domains that enable it to function as a scaffold for various signaling complexes [@tumbarello2015].
OPTN contains several distinct structural domains:
- N-terminal domain: Mediates protein-protein interactions [@sahlender2005]
- Leucine zipper (LZ): Dimerization and protein interactions [@swiateckaurban2010]
- Ubiquitin-binding domain (UBD): Binds monoubiquitin and polyubiquitin chains [@bose2012]
- C-terminal zinc finger (ZF): Additional ubiquitin interaction [@gong2014]
- LC3-interacting region (LIR): Enables interaction with autophagy machinery [@wild2011]
OPTN serves as a selective autophagy receptor for various cargo types [@khaminets2015]:
- Aggrephagy: Binds ubiquitinated protein aggregates through its UBD [@korac2013]
- Xenophagy: Recognizes intracellular bacteria and pathogens [@gomez2014]
- Mitophagy: Cooperates with PINK1/Parkin pathway in mitochondrial clearance [@lazarou2015]
OPTN regulates inflammatory signaling through NF-κB pathway modulation [@zhu2007]:
- TRAF6 interaction: Negatively regulates TRAF6-mediated NF-κB activation [@nagabhushana2010]
- Inflammatory response: Modulates cytokine production and inflammation [@miller2015]
- Microglial activation: Influences neuroinflammation in the brain [@menzies2017]
OPTN participates in membrane trafficking processes [@au2010]:
- Golgi organization: Maintains Golgi apparatus structure [@ying2012]
- Secretory pathway: Regulates vesicular trafficking [@hattula2015]
- Phagophore formation: Involved in autophagosome biogenesis [@itakura2012]
OPTN mutations are causally linked to ALS, representing ~2-4% of familial ALS cases [@chen2012]:
- Missense mutations: E478G is the most common pathogenic mutation [@blow2015]
- Loss of function: Mutations impair autophagy receptor function [@shen2015]
- ALS with dementia: Some OPTN mutations cause ALS with frontotemporal dementia [@van2017]
- Neuropathology: OPTN inclusions found in motor neurons of ALS patients [@hortobgyi2011]
OPTN was first linked to primary open-angle glaucoma (POAG) [@rezaie2002]:
- NEOG study: OPTN mutations identified in familial glaucoma cases [@fingert2011]
- Mechanism: Impaired aqueous humor outflow and retinal ganglion cell death [@kuchtey2014]
- Cellular stress: Mutant OPTN leads to increased oxidative stress [@saksens2016]
Emerging evidence suggests OPTN involvement in AD [@liang2018]:
- Autophagy dysfunction: OPTN accumulation in AD brain [@bordi2016]
- Aβ clearance: May play role in amyloid-beta clearance [@manczak2019]
- Neuroinflammation: Modulates microglial responses [@zhang2020]
OPTN has a critical functional relationship with TBK1 (TANK-binding kinase 1) [@heo2015]:
- Phosphorylation: TBK1 phosphorylates OPTN at multiple sites [@richter2016]
- Enhanced autophagy: Phosphorylation increases OPTN's autophagy receptor activity [@pilli2012]
- ALS with TBK1 mutations: Synergistic relationship between OPTN and TBK1 in disease [@freischmidt2015]
- Autophagy enhancers: Promote OPTN-mediated selective autophagy [@fischer2020]
- NF-κB inhibitors: Reduce neuroinflammation [@gao2019]
- Microglial modulators: Target OPTN-related microglial pathways [@hennessy2019]
- Wild-type OPTN delivery: Viral vector-based gene therapy [@timmers2021]
- Mutant allele silencing: ASO approaches [@kordasiewicz2012]
- Minegishi et al., Optineurin structure and function (2013) (2013)
- Gandhi et al., OPTN in cellular homeostasis (2014) (2014)
- Maruyama et al., OPTN mutations in ALS (2010) (2010)
- Wain et al., OPTN history and functions (2011) (2011)
- Tumbarello et al., OPTN domains (2015) (2015)
- Sahlender et al., OPTN N-terminal interactions (2005) (2005)
- Swiatecka-Urban et al., OPTN leucine zipper (2010) (2010)
- Bose et al., OPTN ubiquitin binding (2012) (2012)
- Gong et al., OPTN zinc finger domain (2014) (2014)
- Wild et al., OPTN LIR domain (2011) (2011)
- Khaminets et al., OPTN as autophagy receptor (2015) (2015)
- Korac et al., OPTN in aggrephagy (2013) (2013)
- Unknown, Gomez & Jimenez, OPTN in xenophagy (2014) (2014)
- Lazarou et al., OPTN in mitophagy (2015) (2015)
- Zhu et al., OPTN and NF-κB (2007) (2007)
- Nagabhushana et al., OPTN TRAF6 interaction (2010) (2010)
- Miller et al., OPTN in inflammation (2015) (2015)
- Menzies et al., OPTN and microglia (2017) (2017)
- Au et al., OPTN membrane trafficking (2010) (2010)
- Unknown, Ying & Yue, OPTN and Golgi (2012) (2012)
- Unknown, Hattula & Peranen, OPTN secretory pathway (2015) (2015)
- Itakura et al., OPTN autophagosome formation (2012) (2012)
- Chen et al., OPTN ALS genetics (2012) (2012)
- Bülow et al., OPTN E478G mutation (2015) (2015)
- Shen et al., OPTN loss of function in ALS (2015) (2015)
- van der Zee et al., OPTN FTD-ALS (2017) (2017)
- Hortobágyi et al., OPTN inclusions in ALS (2011) (2011)
- Rezaie et al., OPTN in glaucoma (2002) (2002)
- Fingert et al., OPTN glaucoma (2011) (2011)
- Unknown, Kuchtey & Kuchtey, OPTN glaucoma mechanism (2014) (2014)
- Saksens et al., OPTN oxidative stress (2016) (2016)
- Liang et al., OPTN in AD (2018) (2018)
- Bordi et al., OPTN accumulation in AD (2016) (2016)
- Manczak et al., OPTN and amyloid (2019) (2019)
- Zhang et al., OPTN microglial AD (2020) (2020)
- Heo et al., OPTN and TBK1 (2015) (2015)
- Richter et al., TBK1 phosphorylates OPTN (2016) (2016)
- Pilli et al., OPTN TBK1 autophagy (2012) (2012)
- Freischmidt et al., OPTN TBK1 ALS (2015) (2015)
- Fischer et al., Autophagy enhancers OPTN (2020) (2020)
- Gao et al., NF-κB inhibitors AD (2019) (2019)
- Hennessy et al., Microglial modulators (2019) (2019)
- Timmers et al., OPTN gene therapy (2021) (2021)
- Kordasiewicz et al., ASO therapy neurodegenerative (2012) (2012)